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ABSTRACT: Sigma receptors (SRs) are recognized as valuable
targets for the treatment of neurodegenerative disorders. A series
of novel SRs ligands were designed by combining key
pharmacophoric amines (i.e., benzylpiperidine or benzylpiper-
azine) with new 1,3-dithiolane-based heterocycles and their
bioisosters. The new compounds exhibited a low nanomolar
affinity for sigma-1 and sigma-2 receptors. Five selected
compounds were evaluated for their neuroprotective capacity on
SH-SY5Y neuroblastoma cell line. They were able to counteract
the neurotoxicity induced by rotenone, oligomycin and NMDA.
Competition studies with PB212, a S1R antagonist, confirmed the involvement of S1R in neuroprotection from the oxidative stress
induced by rotenone. Electrophysiological experiments performed on cortical neurons in culture highlighted the compounds ability
to reduce NMDA-evoked currents, suggesting a negative allosteric modulator activity toward the NMDA receptor. Altogether these
results qualify our novel dithiolane derivatives as potential agents for fighting neurodegeneration.
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Neurodegeneration is a heterogeneous group of disordersincluding Alzheimer’s disease (AD) and related
dementia. According to the WHO around 50 million people
worldwide are affected by dementia and nearly 10 million new
cases are diagnosed every year.1 All drugs currently used in AD
therapy are twenty-years old, have poor efficacy in preventing
the progress of the disease, act exclusively on the symptoms,
and present adverse side effects.2 Thus, there is an urgent need
to identify novel targets and drugs for a disease-modifying
therapy. The progressive loss of structure and/or function of
neurons is the prototypical event behind neurodegeneration.3
Neurotoxicity induced by abnormal production of reactive
oxygen species (ROS) is one the major causes of neuron loss
and reflects an alteration of the mitochondrial respiratory chain
activity.4 Oxidative cellular stress physiologically activates the
sigma-1 receptor (S1R), a chaperone protein, mainly expressed
in mitochondria-associated endoplasmic reticulum (ER)
membranes.5 This receptor triggers or amplifies several cellular
responses, including calcium homeostasis, reduction of
glutamate release, ROS, nitric oxide (NO), microglial activity,
and upregulation of antiapoptotic genes (i.e., Bcl-2), leading to
neuroprotective effects.6−8 Indeed, S1R agonists have demon-
strated neuroprotective properties using in vivo models of AD.9
In addition, increasing evidence suggests that modulating the
sigma-2 receptor (S2R) can provide beneficial effects in
neurodegenerative diseases.10 Among the numerous molecular
targets that have been correlated with neurodegenerative
disorders, also N-methyl-D-aspartate (NMDA) receptor plays a
relevant role.11 A partnership between S1Rs and NMDA
receptors leading to beneficial outcomes in neurodegeneration
has been demonstrated.12 Over the last 10 years, our group has
developed an extensive library of SR modulators combining
different substituted five-membered heterocyclic rings with a
broad range of amines (i.e., benzylpiperidine and benzylpiper-
azine).13−15 Among the previously synthesized compounds, I−
III (Table 1) were of particular interest. They behave as S1R
agonists, with I and II showing high affinity for S1R (Ki = 0.74
and 1.3 nM, respectively) and moderate affinity for S2R
subtype (S1R/S2R selectivity: 47 and 72, respectively),
whereas compound III showed a low nanomolar affinity
against both SR subtypes (KiS1R= 12 nM and KiS2R = 5.0
nM).14 Molecular docking studies highlighted that a salt bridge
between the protonated nitrogen atom of the benzylpiper-
azine/piperidine moiety and Glu172 is essential for the binding
to S1R.16,17 The nature of the pharmacophoric amine
(benzylpiperidine or benzylpiperazine) guided the binding
mode within the S1R binding site. While the piperazine
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derivatives (i.e., I and II) positioned the spirocyclic moiety in
the primary hydrophobic pocket delimitated by Met93,
Tyr103, Ile 178, and Ala 185, the piperidine derivatives (i.e.,
III) exhibited a reverse docking mode with the benzyl moiety
into the primary pocket (Figure 1A and Figure SI-1A).14 To
better investigate the structure activity relationships (SAR) of
this SRs ligand series, herein we expanded the library by
combining the pharmacophoric amines with dithiolane rings
and their bioisosters. Considering the binding mode of
compound III at S1R, 17 novel analogues were prepared
modifying the spirocyclic moiety (Figure 1B) and aiming to
clarify the steric and electrostatic properties necessary for
strong interactions within the secondary hydrophobic pocket
(compounds 1−9, Table 1). In accordance with our mixed
ligand/structure-based investigation, the secondary hydro-
phobic pocket is able to accommodate bulky groups, as also
proposed by Glennon’s pharmacophoric model.14,18 In
particular cycloaliphatic (pentane, eptane) and cycloaromatic
groups (dihydro-indene, tetrahydro-naphtalene, benzo[7]-
annulene, fluorene) were introduced to progressively increase
the structural rigidity. This strategy was successfully applied to
haloperidol-constrained SR ligands providing compounds with
enhanced affinity and selectivity for the S2R subtype.14 In
addition the structural simplification of the spiro-portion was
investigated in both benzylpiperazine and benzylpiperidine
Table 1. Chemical Structure and Binding Affinity (Ki in nM) for S1R and S2R of compounds I−III and 1−13
aSD is within ±10%. bBinding performed with [3H]pentazocine 3.0 nM. cBinding performed with [3H]ditolylguanidine 3.0 nM. dCompounds were
tested as oxalate salts.
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series (compounds 8−11). The corresponding dioxolane
bioisosters (12 and 13) were also prepared.
For the overall library, the most relevant physicochemical
properties and drug-likeness were determined in silico using
the SwissADME web utility.19 Prediction of blood−brain
barrier (BBB) permeability has been pointed out as an
important parameter in the design of neuroprotective
compounds. Assuming no more than one violation to the
Lipinski’s rule of 5,20 all the compounds showed a good
druggability and were predicted to passively permeate the BBB
(Table SI-1). The synthetic strategies for the synthesis of
compounds 1−13 are described in Scheme 1. Compounds 1−
13 are the oxalate salts obtained by reaction of the respective
free amines 14−26 with anhydrous oxalic acid, followed by
crystallization from dry diethyl ether. The free amines 14−26
were obtained by standard SN2 reaction between the
appropriate aliphatic chloride 27−36 and 4-benzylpiperidine
(for compounds 14−22, 25) or 1-benzylpiperazine (for 23, 24,
and 26). The amines 16−18 and 20, characterized by the
presence of two stereogenic centers, were obtained as a
mixture of two diasteromeric pairs. The two racemates were
separated by flash chromatography and the E/Z isomerism
assigned by NOESY experiments. With the exception of 36,
which was obtained directly by condensation of acetone with
3-chloro-1,2-propandiol, 4-(chloromethyl)-1,3-dithiolanes 27−
35 were prepared by treatment of the respective alcohols 37−
45 with thionyl chloride. Compounds 37−44 were obtained by
condensation of the appropriate ketone with 2,3-dimercapto-
propan-1-ol using HClO4 absorbed on silica gel as catalyst.
This procedure did not allow us to obtain 45 which was
instead prepared by condensation of formaldehyde diethyl
acetal with 2,3-dimercapto-propan-1-ol in the presence of
cobalt chloride and trimethylsilyl chloride. All the synthesized
compounds were evaluated for binding affinity toward S1R and
Figure 1. (A) Overview of the S1R binding site with the key Glu172
and the two main hydrophobic sites, and superimposition of
Glennon’s pharmacophore distances. The binding orientation of III,
as representative for benzylpiperidine derivatives, predicted by
docking calculations, is schematically shown. (B) Library design and
expansion by combining the pharmacophoric amines with dithiolane
rings and their bioisosters.
Scheme 1a
aReagents and conditions: (a) appropriate ketone (1 equiv), 2,3-dimercapto-1-propanol (1.2−1.4 equiv), HClO4 on SiO2 (0.008−0.05 equiv),
neat, N2, MW irradiation, 50-80 °C, 15-60 min, 24-98% yield; (b) formaldehyde diethyl acetal (1 equiv), 2,3-dimercapto-1-propanol (1.2 equiv),
CoCl2 (0.5 equiv), TMCS (0.8 equiv), dry acetonitrile, N2, r.t., 75 min, 24% yield; (c) thionyl chloride (1.2 equiv), DMF (cat.), dry
dichloromethane, N2, 0 °C, 90 min, quant. yield; 69% (for 35); (d) acetone (10 equiv), 3-chloro-propan-1,2-diol (1 equiv), HClO4 on SiO2 (0.6
equiv), dry dichloromethane, N2, MW irradiation, 80 °C, 100 min, 59% yield; (e) 4-benzylpiperidine or 1-benzylpiperazine (2 equiv), K2CO3 (2
equiv), KI (cat.), dry acetonitrile, MW irradiation, 130 °C, 10−40 min, 7-64% yield; (f) oxalic acid (1.2 equiv for piperidine or 2.2 equiv for
piperazine), dry diethyl ether, r.t., 48 h, 32−90% yield.
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S2R in a radioligand displacement assay using [3H]-(+)-
pentazocine to selectively mark S1R and [3H]-ditolylguanidine,
in the presence of cold (+)-pentazocine, to mark S2R. The
binding affinities, expressed as inhibition constant (Ki), are
reported in Table 1. The compounds showed nanomolar
affinity at both SR subtypes with Ki values ranging from 195 to
0.5 nM for S1R, and from 182 to 0.59 nM for S2R.
Compounds 9, 11, and 13 exhibited a moderate selectivity
for S1R over S2R with a S1R/S2R ratio of 24, 43, and 34,
respectively. The binding results, supported by docking
calculation, allowed us to disclose some structure−activity
relationships. The narrowing and expansion of the carbocyclic
ring (1 and 2, respectively) preserved the high affinity of the
lead compound III at both subtypes (KiS1R = 4.2 and 1.7 nM
and KiS2R = 3.0 and 8.1 nM, respectively). Compounds 1 and
2 presented a binding mode analogue to that of compound III
(Figure SI-1B). In contrast, scaffold rigidification obtained by
condensing one (for compounds 3−5) or two (for 6) benzene
rings caused a significant drop in affinity for both SR subtypes.
Similarly, opening of the spirocyclic portion into the more
flexible derivative 7 led to a reduced affinity at both subtypes
(KiS1R = 68 and 76 nM and KiS2R = 85 and 63 nM for E and
Z isomers, respectively). These results highlighted that a bulky
aromatic ring, condensed or appended to the 1,3-dithiolane
core, is detrimental for affinity. As suggested by docking
calculations, although the secondary binding site of S1R might
tolerate bulky groups, the rigid and constrained conformation
assumed by these molecules prevented an easy fit within the
pocket. Thus, compounds 3−7 assumed the reverse binding
mode, as previously observed for I and II.
The benzylpiperidine ring was located in the secondary site,
while the bulkier spirocyclic moieties were accommodated in
the wider and longer primary hydrophobic pocket. However,
this led to an unsuitable alignment between the protonated
piperidine nitrogen atom and the Glu172, justifying the
reduced affinity of compounds 3−7 compared to III (Figure
SI-1C). No diastereoselectivity between the E/Z isomers was
observed. The structural simplification of the 1,4-dithiaspiro-
decane moiety of III with a less sterically hindered and more
flexible structure (8 and 9) resulted in a subnanomolar affinity
(KiS1R = 2.0 and 0.59 nM and KiS2R = 0.5 and 12 nM, for 8
and 9, respectively). Compounds 8 and 9 showed a binding
mode comparable to that described for III, 1−3 (Figure 2A).
However, the opening of the cycloalkylspiro portion induced a
slight shift of these compounds toward the secondary pocket,
(i) straightening the salt bridge between the protonated amine
and Glu172 and (ii) allowing the benzyl-tail to be engaged in
an additional π−π face-to-edge stacking with Tyr103.
The high S1R affinity was maintained by replacing the
piperidine with the piperazine (Ki = 0.6 and 2.1 nM for 10 and
11, respectively). As expected, the presence of the
benzylpiperazine reverted the binding poses of 10 and 11 in
order to efficiently align the protonated nitrogen with Glu172
(Figure 2B). This binding mode fulfilled the Glennon’s
pharmacophore, preserving the distances of the two hydro-
phobic groups of the molecule to the central protonated site.
Finally, no significant differences in terms of affinity and
selectivity were observed by replacing the dithiolane (10 and
11) with the dioxolane bioisoster (12 and 13, Figure SI-1D).
To sum up, the SAR investigation pointed out that (i)
structural simplification of the spiro portion allowed achieving
sub/low nanomolar affinity for SRs, while (ii) the introduction
of bulky groups led to a drop in affinity for both SR subtypes.
Recent studies suggested that both S1R and S2R modulators
might have a positive effect in neuroprotection.5,10 Therefore,
we evaluated the in vitro neuroprotective capacity of selected
high affinity ligands. According to the binding affinities,
compounds I, II, and 11 were chosen for their S1R selectivity,
whereas III and 9 were selected as S1R/S2R mixed
compounds. ROS are normally produced in neurons and the
resulting oxidative stress is one of the major contributors to
cell death in neurodegenerative disorders. Herein, we assessed
the capability of compounds I−III, 9, and 11 to protect SH-
SY5Y cells from oxidative damage induced by two potent ROS
generating insults, namely rotenone and oligomycin.21 At first,
the selected compounds were investigated, as single agents, for
cytotoxicity (Table SI-2) in human SH-SY5Y cell line to define
the experimental doses for the neuroprotective studies.22 The
neuroprotective capacity was reported as percentage of cell
viability after treatment with the compound in the presence of
the toxic stimuli.
At 1 μM concentration, compounds I−III and 11 were able
to significantly prevent cell damage induced by rotenone
(Figure 3). Interestingly, I and II were effective also at the
higher dose of 5 μM. To investigate the role of S1R in this
process, the neuroprotective activity of our molecules was
tested in the presence of PB212, a S1R antagonist.23 All
compounds displayed a significant decrease of their neuro-
protective capacity in combination with PB212 (P < 0,001 at 1
μM). Altogether these results suggested the involvement of
sigma receptors in the neuroprotective effect of the proposed
compounds.
Figure 2. Docking of compound 9 (A, stick, violet carbon) and 11 (B,
stick green carbon) into S1R binding site. The reference crystal
structure used for the docking calculation (PDB ID: 6DK1) of S1R is
shown in teal cartoon. Important interacting residues are in stick
representation. Model atoms except for carbons are color-coded with
protein carbons (teal), oxygen (red), nitrogen (blue), and sulfur
(yellow). Bridge salt and π−π interactions are represented as yellow
and magenta dotted lines, respectively. Part of the β-barrel has been
hidden for a clearer visualization of the binding site.
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When oligomycin (2.5 μM) was used as a toxic stimulus,
only compound II at 5 μM was able to protect cells from
death, with a cell viability >60% (Figure SI-2). In addition, the
neuroprotective potential of our ligands was evaluated using
NMDA as a toxic insult.24 The neuroblastoma cells were
incubated for 24 h in the presence of 250 μM of NMDA
(corresponding to its IC50, Table SI-2) and four different
concentrations of compounds I−III, 9 ,and 11 (ranging from
0.1 to 5 μM). Memantine was used as a positive control at the
same concentrations of the tested molecules.25 All the tested
compounds demonstrated a neuroprotective effect against
NMDA stimuli at concentrations <1 μM (Figure 4). I, III, and
11 showed the highest neuroprotective activity, being able to
recover >85% of the cell viability at the two lowest doses (0.1
and 0.5 μM). Moreover, I and III exhibited a dose−response
profile similar to that of memantine. Compounds II and 9
showed a lower cytoprotective activity compared to I, III, and
11 (72−75% of the cell survival at 0.5 and 1 μM). All tested
compounds, including memantine, did not significantly
increase cell viability at a 5 μM concentration.
Compounds III and 11, showing the best neuroprotective
activity, were selected to further demonstrate the involvement
of SRs in their neuroprotective effects against NMDA toxicity.
In the presence of PB212, the neuroprotective activity of both
compounds (tested at 0.1 μM) significantly decreased (P <
0,001), even though it was not completely abolished for
compound III (Figure 5).
In the literature, examples of SR ligands with promiscuous
affinity for NMDA receptors are reported; thus, the neuro-
protective capacity of III could be related to its activity on
NMDA receptors.12 To test this hypothesis, we used a patch
clamp technique in primary culture of cortical neurons and
investigated the ability of compounds I−III to modulate
NMDA-evoked current.26 Compound I reduced NMDA-
evoked currents of 34 and 18% at a concentration of 0.1 and
1 μM, respectively (Figure 6).
Similarly, low concentrations of compounds II and III
decreased NMDA-evoked currents (−20 ± 4% for II and −50
± 6% for III), suggesting that the neuroprotection exerted by
these compounds against NMDA-induced cytotoxicity could
be achieved through a reduction of NMDA receptor-mediated
ion flux. On the contrary, compound I at 10 μM increased
(110%) NMDA current (Figure 6). This effect could explain
the lack of neuroprotection of I at high concentrations (Figure
4). These data support the hypothesis that compounds I−III,
in addition to interacting with the sigma receptors, can also act
as negative allosteric modulators of NMDA receptors.
In summary, we identified novel high affinity ligands and
assessed their neuroprotective effects. Compounds II and 11
displayed an excellent affinity for S1R (Ki = 1.3 and 2.1) and
selectivity over S2R (72 and 43, respectively). II was able to
protect neuronal cells from three different cytotoxic insults,
namely rotenone, oligomycin, and NMDA. In the case of
rotenone, the neuroprotective activity of the tested compounds
was completely reversed after treatment with PB212, a S1R
antagonist, highlighting that its effect is fully mediated by SRs.
This is consistent with a S1R agonist activity.14 However, for
NMDA induced toxicity, PB212 did not completely abolish the
neuroprotective capacity of III, suggesting that its effect could
be mediated by an either direct or indirect modulation of the
NMDA receptor. Interestingly, compounds bearing the 4-
benzylpiperazine basic moiety (I, II, and 11) displayed strong
Figure 3. Neuroprotective effect, expressed as % of cell viability (SH-
SY5Y cells) of the tested compounds I−III, 9, and 11 at 1.0 and 5.0
μM in the presence of rotenone (25 μM) and a combination of
rotenone and the S1R antagonist, PB212 (5 μM). Each bar represents
the mean ± SD of three independent experiments: ***p < 0.001 vs
rotenone alone, †††p < 0.001, ††p < 0.01, and †p < 0.05.
Figure 4. Neuroprotective effect, expressed as % of cell viability (SH-
SY5Y cells) of the tested compounds I−III, 9, and 11 at 0.1, 0.5, 1.0,
and 5.0 μM in the presence of NMDA 250 μM (IC50 at 24 h).
Memantine was used as positive control. Each bar represents the
mean ± SD of three independent experiments: *p < 0.05, **p < 0.01,
***p < 0.001 vs NMDA alone.
Figure 5. Neuroprotective effect, expressed as % of cell viability (SH-
SY5Y cells), of the tested compounds III and 11 (0.1 μM) in the
presence of NMDA (250 μM) and a combination of NMDA and
PB212 (5 μM). Each bar represents the mean ± SD of three
independent experiments: ***p < 0.001 vs NMDA alone, †††p <
0.001 and ††p < 0.01, φφφp < 0.001.
ACS Medicinal Chemistry Letters pubs.acs.org/acsmedchemlett Letter
https://dx.doi.org/10.1021/acsmedchemlett.0c00129
ACS Med. Chem. Lett. 2020, 11, 1028−1034
1032
S1R affinities together with in vitro neuroprotection, with II
being the best one. Altogether, our results encourage the
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